4//SEC Filing
ANDERSON MICHAEL S 4
Accession 0001144204-18-044801
CIK 0001012477other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 8:01 PM ET
Size
15.7 KB
Accession
0001144204-18-044801
Insider Transaction Report
Form 4
ANDERSON MICHAEL S
DirectorChief Executive Officer
Transactions
- Sale
ADSs
2018-08-10$4.91/sh−16,297$79,953→ 248,953 total
Holdings
- 275,000
Stock Option (right to buy)
Exercise: $6.93Exp: 2022-03-08→ ADSs (275,000 underlying) - 80,500
Stock Option (right to buy)
Exercise: $4.07Exp: 2023-02-01→ ADSs (80,500 underlying) - 200,000
Stock Option (right to buy)
Exercise: $16.30Exp: 2024-12-11→ ADSs (200,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $14.35Exp: 2025-12-10→ ADSs (200,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $10.40Exp: 2026-12-14→ ADSs (200,000 underlying) - 150,000
Stock Option (right to buy)
Exercise: $8.95Exp: 2027-12-12→ ADSs (150,000 underlying)
Footnotes (11)
- [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- [F10]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
- [F11]Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
- [F2]On August 10, 2018, the reporting person sold 16,297 ADSs in connection with the payment of certain withholding taxes related to the vesting of restricted ADSs that were granted to the reporting person on August 10, 2016 (such grant was reported by the reporting person on a Form 4 filed on August 12, 2016).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.89 to $5.01, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
- [F4]Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which were issued to the reporting person on the second anniversary of the grant date; (c) 30,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and [continued in footnote 5 below]
- [F5](d) 25,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 16,666 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 8,334 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
- [F6]Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date.
- [F7]Options became exercisable in four equal amounts over the first four anniversaries after the 02/01/2013 grant date.
- [F8]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- [F9]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeother
Related Parties
1- filerCIK 0001144178
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 8:01 PM ET
- Size
- 15.7 KB